Company Listing
Dicerna Pharmaceuticals

Dicerna is applying its proprietary RNAi technology to discover and develop innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. This second-generation gene-silencing technology can knock down the expression of a targeted gene in a way that is highly selective, specific and more potent than other RNAi approaches. The company's lead programme is currently in Phase I trials as a potential cancer treatment. Dicerna went public in January 2014.

 

 

BACK
Location
Watertown, Massachusetts
CEO
Douglas Fambrough
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Dicerna is applying its proprietary RNAi technology to discover and develop innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. This second-generation gene-silencing technology can knock down the expression of a targeted gene in a way that is highly selective, specific and more potent than other RNAi approaches. The company's lead programme is currently in Phase I trials as a potential cancer treatment. Dicerna went public in January 2014.

 

 

Location
Watertown, Massachusetts
CEO
Douglas Fambrough
Website Address
BACK
 
Copyright Abingworth 2017